- Home
- WU vs VRDN Comparison
WU vs VRDN Comparison
Compare WU & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | VRDN |
|---|---|---|
| Founded | 1851 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WU | VRDN |
|---|---|---|
| Price | $7.61 | $19.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $9.00 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 7.1M | 1.8M |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $4,050,700,000.00 | $5,706,000.00 |
| Revenue This Year | $8.50 | $13.73 |
| Revenue Next Year | $4.73 | $279.00 |
| P/E Ratio | $40.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.91 | $13.18 |
| 52 Week High | $10.35 | $34.29 |
Technical Indicators
Market Signals| Indicator | WU | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 61.06 |
| Support Level | $8.05 | $15.58 |
| Resistance Level | $8.14 | $20.00 |
| Average True Range (ATR) | 0.30 | 0.79 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 27.73 | 87.97 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.